Eluforsen
- Generic Name
- Eluforsen
- Drug Type
- Biotech
- CAS Number
- 2101868-82-8
- Unique Ingredient Identifier
- V30WFP6S2Y
- Background
Eluforsen is under investigation in clinical trial NCT02532764 (Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients).
Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- ProQR Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT02564354
- Locations
- 🇺🇸
Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States
🇧🇪U.Z. Leuven, Leuven, Belgium
🇺🇸National Jewish Health, Denver, Colorado, United States
Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- ProQR Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT02532764
- Locations
- 🇺🇸
University of Southern California USC - Keck School of Medicine, Los Angeles, California, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath